Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026)
Neumora Therapeutics' Income from Continuing Operations came in at -$43.08 million for Q2 2026, compared with -$52.73 million a year earlier.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Neumora Therapeutics reported Income from Continuing Operations of -$212.75 million; for FY2025, it came in at -$236.93 million.
- Going back by year, Income from Continuing Operations was -$243.79 million in FY2024, -$235.93 million in FY2023 and -$130.9 million in FY2022.
- The Q2 2026 figure represents the highest quarterly Income from Continuing Operations since Q2 2023.
- Business Quant data shows NMRA's Income from Continuing Operations at -$53.46 million (Q1 2026), -$59.45 million (Q4 2025) and -$56.76 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Neumora Therapeutics | 129.65 Mn | 129.65 Mn | - | -43.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.08 Mn |
| Mar 31, 2026 | -53.46 Mn |
| Dec 31, 2025 | -59.45 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.73 Mn |
| Mar 31, 2025 | -67.99 Mn |
| Dec 31, 2024 | -58.82 Mn |
| Sep 30, 2024 | -72.55 Mn |
| Jun 30, 2024 | -58.70 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.46 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -39.17 Mn |
| Dec 31, 2022 | -30.72 Mn |
| Sep 30, 2022 | -29.20 Mn |
API Access
Neumora Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();